The FDA has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate), from Gilead Sciences, for use in certain...
The CHMP has adopted a positive opinion for the once-daily single-tablet regimen, Eviplera, combining Gilead's Truvada (emtricitabine and tenofovir disoproxil...
The EMA has granted marketing authorisation for the combination drug Eviplera, from Gilead Sciences, for HIV-1 infection.Eviplera is a once-daily...
The FDA has approved Harvoni (ledipasvir + sofosbuvir) for use in patients with hepatitis C virus (HCV) infection co-infected with...